Trial · NCT04413344
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 20
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety (Incidence and severity of adverse events and adverse reactions) | Until Week 50 (end of trial) | to assess safety |
| Primary | Severe impairment battery-Japanese version (SIB-J) | Until Week 20 and 36 | to assess cognitive function |
| Primary | Neuropsychiatric Inventory (NPI) | Until Week 20 and 36 | to assess behavioral and psychiatric symptoms of dementia |
| Secondary | Mental Function Impairment Scale (MENFIS) | Until Week 20 and 36 | to assess cognitive function |
| Secondary | Mini-Mental State Examination-Japanese (MMSE-J) | Until Week 20 and 36 | to assess cognitive function |
| Secondary | Disability Assessment for Dementia (DAD) | Until Week 20 and 36 | to assess activities of daily living |
| Secondary | Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III | Until Week 20 and 36 | to assess motor symptoms and signs |
| Secondary | Apathy Scale | Until Week 20 and 36 | to assess apathy |
| Secondary | Plasma Aβ protein concentration | Until Week 20 and 36 | to assess Aβ protein metabolism |
| Secondary | Plasma NfL protein concentration | Until Week 20 and 36 | to assess neurodegeneration |
| Secondary | Plasma Total Tau, Plasma p-Tau concentration | Until Week 20 and 36 | to assess tau protein metabolism |
| Secondary | Cerebrospinal fluid (CSF) Aβ concentration | Until Week 36 | to assess Aβ protein metabolism |
| Secondary | CSF Total Tau, CSF p-Tau concentration | Until Week 36 | to assess tau protein metabolism |
| Secondary | Blood bromocriptine concentration | Until Week 20 and 36 | to assess safety |
| Other | Wearable physical activity meter | Until Week 20 and 36 | to assess activities of daily living |
| Other | Finger tapping sensor readout | Until Week 20 and 36 | to assess finger tapping |
| Other | Brain amyloid PET image | Until Week 36 | to assess Aβ protein metabolism |
| Other | Brain tau PET image | Until Week 36 | to assess tau protein metabolism |
| Other | Upper motor neuron burden score | Until Week 20 and 36 | to assess spasticity |
| Other | Plasma Aβ-related peptides concentration | Until Week 20 and 36 | to assess Aβ protein metabolism |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04413344/registered